시장보고서

상품코드

1605835

SGLT2 억제제 시장 규모, 점유율, 동향, 산업 분석 보고서 : 적응증별, 약물별, 유통 채널별, 지역별 - 시장 예측(2025-2034년)

SGLT2 Inhibitors Market Size, Share, Trends, Industry Analysis Report: By Indication (Cardiovascular, Chronic Kidney Disease, Type 2 Diabetes, and Others), Drug, Distribution Channel, and Region - Market Forecast, 2025 - 2034

발행일: 2024년 11월 | 리서치사:

Polaris Market Research | 페이지 정보: 영문 118 Pages | 배송안내 : 1-2일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면 SGLT2 억제제 세계 시장 규모는 2034년까지 327억 5,000만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.

나트륨-포도당 공수송체 2(SGLT2) 억제제 시장은 제2형 당뇨병(T2D), 심부전, 만성 신장병(CKD)의 유병률 증가로 인해 세계 제약 산업에서 중요한 부문으로 부상하고 있습니다. 역할을 하는 단백질인 나트륨-포도당 공수송체2를 억제하여 작용하는 약제군입니다.

SGLT2 억제제 시장은 신장의 포도당 재흡수를 억제하여 혈당 수치를 낮추고 제2형 당뇨병(T2D) 치료에 대한 효능이 증가함에 따라 큰 성장세를 보이고 있습니다. 이러한 성장의 배경에는 비만율 증가, 좌식 생활, 고령화, 건강에 해로운 식습관 등이 있습니다. 유전적 소인, 도시화, 경제적 격차도 북미 및 전 세계 당뇨병 환자의 급증에 기여하고 있습니다. 이로 인해 SGLT2 억제제에 대한 수요가 증가하고 있습니다.

COVID-19 팬데믹은 당뇨병 환자들이 질병을 관리하고 심각한 합병증 위험을 줄이기 위해 효과적인 치료법을 찾으면서 SGLT2 억제제의 채택을 더욱 가속화했습니다. 또한, COVID-19 사태로 인해 온라인 약국 이용이 급증하면서 이들 약품에 대한 접근이 쉬워졌습니다. 또한 유리한 상환 정책, 규제 당국의 승인 및 제형의 지속적인 기술 혁신이 시장을 더욱 강화했습니다.

SGLT2 억제제 시장 보고서 하이라이트

2024년 SGLT2 억제제 시장에서 제2형 당뇨병 분야가 가장 큰 매출 점유율을 차지했습니다. 도시화가 진행됨에 따라 운동량 감소, 가공식품 소비 증가, 스트레스 수준 증가와 같은 생활습관의 변화가 자주 발생합니다. 이러한 요인들은 비만과 제2형 당뇨병의 유병률 증가에 기여하며 SGLT2 억제제 시장을 크게 견인하고 있습니다.

온라인 약국 부문은 예측 기간 동안 가장 높은 CAGR로 성장하고 있습니다. 온라인 약국은 온라인 운영에 따른 간접비 절감으로 인해 경쟁 가격 및 의약품 할인을 제공하는 경우가 많습니다.

2024년 북미 SGLT2 억제제 시장은 만성 스트레스의 증가와 정신 상태의 악화로 인해 가장 큰 시장을 차지했습니다. 또한, 북미에서 당뇨병 환자의 유병률이 증가함에 따라 SGLT2 억제제에 대한 수요가 증가하고 있습니다.

아시아태평양은 아시아태평양에서 가장 빠른 성장세를 보이고 있습니다. 이 지역의 각국 정부는 의료 인프라에 대한 투자를 늘리고 접근성과 질을 높이기 위한 노력을 기울이고 있습니다. 이러한 노력은 의약품 시장과 SGLT2 억제제와 같은 의약품의 채택을 뒷받침하고 있습니다.

유통 채널 현황
SGLT2 억제제 시장 역학
- 성장 촉진요인과 기회
  - 세계의 고령화 진행이 시장 성장을 견인
  - 신약 승인 증가가 시장 전망을 견인
- 성장 억제요인과 과제
  - 고액의 의약품
PESTEL 분석
SGLT2 억제제 시장 유통 채널 동향
밸류체인 분석
COVID-19의 영향 분석

제5장 세계의 SGLT2 억제제 시장 : 적응증별

주요 조사 결과
소개
심혈관
만성 신장병(CKD)
2형 당뇨병
기타

제6장 세계의 SGLT2 억제제 시장 : 약제별

주요 조사 결과
소개
Farxiga (Dapagliflozin)
Inpefa (Sotagliflozin)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Qtern (Dapagliflozin/Saxagliptin)
기타 SGLT2 억제제

제7장 세계의 SGLT2 억제제 시장 : 유통 채널별

주요 조사 결과
소개
병원 약국
온라인 약국
소매 약국

제8장 세계의 SGLT2 억제제 시장 : 지역별

주요 조사 결과
소개
- SGLT2 억제제 시장 평가 : 지역, 2020-2034년
북미
- 북미 : 적응증별, 2020-2034년
- 북미 : 유통 채널별, 2020-2034년
- 북미 : 약제별, 2020-2034년
- 미국
- 캐나다
유럽
- 유럽 : 적응증별, 2020-2034년
- 유럽 : 유통 채널별, 2020-2034년
- 유럽 : 약제별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
아시아태평양
- 아시아태평양 : 적응증별, 2020-2034년
- 아시아태평양 : 유통 채널별, 2020-2034년
- 아시아태평양 : 약제별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
중동 및 아프리카
- 중동 및 아프리카 : 적응증별, 2020-2034년
- 중동 및 아프리카 : 유통 채널별, 2020-2034년
- 중동 및 아프리카 : 약제별, 2020-2034년
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
라틴아메리카
- 라틴아메리카 : 적응증별, 2020-2034년
- 라틴아메리카 : 유통 채널별, 2020-2034년
- 라틴아메리카 : 약물별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카

제9장 경쟁 구도

확대와 인수 분석
- 확대
- 인수
제휴/협업/합의/공개

제10장 기업 개요

AstraZeneca
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
Glenmark Pharmaceuticals Ltd.
Johnson & Johnson Services, Inc.(Janssen Pharmaceuticals, Inc.)
Lexicon Pharmaceuticals, Inc.
Merck & Co., Inc.
Sanofi
TheracosBio, LLC

ksm 24.12.26

The global SGLT2 inhibitors market size is expected to reach USD 32.75 billion by 2034, according to a new study by Polaris Market Research. The report "SGLT2 Inhibitors Market Size, Share, Trends, Industry Analysis Report, By Indication (Cardiovascular, Chronic Kidney Disease (CKD), Type 2 Diabetes, and Others), Drug, Distribution Channel, and Region; Segment Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The sodium-glucose cotransporter 2 (SGLT2) inhibitors market has emerged as a significant segment of the global pharmaceutical industry, driven by the increasing prevalence of type 2 diabetes (T2D), heart failure, and chronic kidney diseases (CKD). SGLT2 inhibitors are a class of drugs that work by blocking the sodium-glucose cotransporter 2, a protein responsible for reabsorbing glucose from the kidneys into the bloodstream

The market for SGLT2 inhibitors is experiencing significant growth due to their increasing efficacy in treating type 2 diabetes (T2D) by inhibiting glucose reabsorption in the kidneys and thereby lowering blood sugar levels. This expansion is attributed to the increasing rising obesity rates, sedentary lifestyles, aging populations, and unhealthy diets. Genetic predisposition, urbanization, and economic differences also contribute to the surge in diabetes cases in North America and globally. Thereby boosting demand for SGLT2 inhibitors.

The COVID-19 pandemic has further accelerated the adoption of SGLT2 inhibitors as diabetic patients sought effective treatments to manage their condition and mitigate the risk of severe COVID-19 complications. Additionally, the pandemic has led to a surge in the use of online pharmacies, facilitating accessibility to these medications. Furthermore, favorable reimbursement policies, regulatory approvals, and ongoing innovations in drug formulations further bolster the market.

SGLT2 Inhibitors Market Report Highlights

In 2024, the type 2 diabetes segment accounted for the largest revenue share in the SGLT2 inhibitors market. Urbanization often leads to lifestyle changes characterized by decreased physical activity, increased consumption of processed foods, and higher stress levels. These factors contribute to the rising prevalence of obesity and type 2 diabetes, significantly driving the SGLT2 inhibitors market.

The online pharmacies segment is growing at the highest CAGR during the forecast period. Online pharmacies often offer competitive pricing and discounts on medications as a result of reduced overhead costs associated with online operations.

In 2024, North America SGLT2 inhibitors market accounted for the largest market due to the increasing chronic stress and poor mental. Additionally, the increasing prevalence of diabetes patients in North America has led to a higher demand for SGLT2 inhibitors in the region.

Asia Pacific accounted for the fastest growth in the market. Governments in the region are increasingly investing in healthcare infrastructure and initiatives to enhance access and quality. These efforts support pharmaceutical markets and the adoption of medications like SGLT2 inhibitors.

The global key market players include AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi; and TheracosBio, LLC.

Polaris Market Research has segmented the SGLT2 inhibitors market report based on indication, drug, distribution channel, and region:

By Indication Outlook (Revenue - USD Billion, 2020 - 2034)

Cardiovascular
Chronic Kidney Disease (CKD)
Type 2 Diabetes
Others

By Drug Outlook (Revenue - USD Billion, 2020 - 2034)

Farxiga (Dapagliflozin)
Inpefa (Sotagliflozin)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Qtern (Dapagliflozin/Saxagliptin)
Other SGLT2 Inhibitors

By Distribution Channel Outlook (Revenue - USD Billion, 2020 - 2034)

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

By Regional Outlook (Revenue - USD Billion, 2020 - 2034)

North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Indonesia
Malaysia
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global SGLT2 Inhibitors Market Insights

4.1. SGLT2 Inhibitors Market - Distribution Channel Snapshot
4.2. SGLT2 Inhibitors Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. The Global Rise of the Aging Population is Driving Market Growth
  - 4.2.1.2. Rising New Drug Approvals Drive Market Outlook
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Cost of Medication
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. SGLT2 Inhibitors Market Distribution Channel Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global SGLT2 Inhibitors Market, by Indication

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
5.3. Cardiovascular
- 5.3.1. Global SGLT2 Inhibitors Market, by Cardiovascular, by Region, 2020-2034 (USD Billion)
5.4. Chronic Kidney Disease (CKD)
- 5.4.1. Global SGLT2 Inhibitors Market, by Chronic Kidney Disease (CKD), by Region, 2020-2034 (USD Billion)
5.5. Type 2 Diabetes
- 5.5.1. Global SGLT2 Inhibitors Market, by Type 2 Diabetes, by Region, 2020-2034 (USD Billion)
5.6. Others
- 5.6.1. Global SGLT2 Inhibitors Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global SGLT2 Inhibitors Market, by Drug

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
6.3. Farxiga (Dapagliflozin)
- 6.3.1. Global SGLT2 Inhibitors Market, by Farxiga (Dapagliflozin), by Region, 2020-2034 (USD Billion)
6.4. Inpefa (Sotagliflozin)
- 6.4.1. Global SGLT2 Inhibitors Market, by Inpefa (Sotagliflozin), by Region, 2020-2034 (USD Billion)
6.5.Invokana (Canagliflozin)
- 6.5.1. Global SGLT2 Inhibitors Market, by Invokana (Canagliflozin), by Region, 2020-2034 (USD Billion)
6.6. Jardiance (Empagliflozin)
- 6.6.1. Global SGLT2 Inhibitors Market, by Jardiance (Empagliflozin), by Region, 2020-2034 (USD Billion)
6.5. Qtern (Dapagliflozin/Saxagliptin)
- 6.5.1. Global SGLT2 Inhibitors Market, by Qtern (Dapagliflozin/Saxagliptin), by Region, 2020-2034 (USD Billion)
6.5. Other SGLT2 Inhibitors
- 6.5.1. Global SGLT2 Inhibitors Market, by Other SGLT2 Inhibitors, by Region, 2020-2034 (USD Billion)

7. Global SGLT2 Inhibitors Market, by Distribution Channel

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
7.3. Hospital Pharmacies
- 7.3.1. Global SGLT2 Inhibitors Market, by Hospital Pharmacies, By Region, 2020-2034 (USD Billion)
7.4. Online Pharmacies
- 7.4.1. Global SGLT2 Inhibitors Market, by Online Pharmacies, By Region, 2020-2034 (USD Billion)
7.5. Retail Pharmacies
- 7.5.1. Global SGLT2 Inhibitors Market, by Retail Pharmacies, By Region, 2020-2034 (USD Billion)

8. Global SGLT2 Inhibitors Market, by Geography

8.1. Key findings
8.2. Introduction
- 8.2.1. SGLT2 Inhibitors Market Assessment, By Geography, 2020-2034 (USD Billion)
8.3. SGLT2 Inhibitors Market - North America
- 8.3.1. North America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
- 8.3.2. North America: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3.3. North America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.3.4. SGLT2 Inhibitors Market - U.S.
  - 8.3.4.1. U.S.: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.3.4.2. U.S.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.3.4.3. U.S.: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.3.5. SGLT2 Inhibitors Market - Canada
  - 8.3.5.1. Canada: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.3.5.2. Canada.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.3.5.3. Canada: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.4. SGLT2 Inhibitors Market - Europe
- 8.4.1. Europe: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
- 8.4.2. Europe.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.3. Europe: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.4. SGLT2 Inhibitors Market - UK
  - 8.4.4.1. UK: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.4.2. UK.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.4.3. UK: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.5. SGLT2 Inhibitors Market - France
  - 8.4.5.1. France: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.5.2. France.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.5.3. France: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.6. SGLT2 Inhibitors Market - Germany
  - 8.4.6.1. Germany: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.6.2. Germany.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.6.3. Germany: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.7. SGLT2 Inhibitors Market - Italy
  - 8.4.7.1. Italy: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.7.2. Italy.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.7.3. Italy: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.8. SGLT2 Inhibitors Market - Spain
  - 8.4.8.1. Spain: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.8.2. Spain.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.8.3. Spain: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.9. SGLT2 Inhibitors Market - Netherlands
  - 8.4.9.1. Netherlands: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.9.2. Netherlands.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.9.3. Netherlands: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.10. SGLT2 Inhibitors Market - Russia
  - 8.4.10.1. Russia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.10.2. Russia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.10.3. Russia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.11. SGLT2 Inhibitors Market - Rest of Europe
  - 8.4.11.1. Rest of Europe: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.11.2. Rest of Europe.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.11.3. Rest of Europe: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.5. SGLT2 Inhibitors Market - Asia Pacific
- 8.5.1. Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.4. SGLT2 Inhibitors Market - China
  - 8.5.4.1. China: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.4.2. China.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.4.3. China: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.5. SGLT2 Inhibitors Market - India
  - 8.5.5.1. India: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.5.2. India.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.5.3. India: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.6. SGLT2 Inhibitors Market - Malaysia
  - 8.5.6.1. Malaysia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.6.2. Malaysia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.6.3. Malaysia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.7. SGLT2 Inhibitors Market - Japan
  - 8.5.7.1. Japan: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.7.2. Japan.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.7.3. Japan: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.8. SGLT2 Inhibitors Market - Indonesia
  - 8.5.8.1. Indonesia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.8.2. Indonesia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.8.3. Indonesia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.9. SGLT2 Inhibitors Market - South Korea
  - 8.5.9.1. South Korea: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.9.2. South Korea: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.9.3. South Korea: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.10. SGLT2 Inhibitors Market - Australia
  - 8.5.10.1. Australia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.10.2. Australia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.10.3. Australia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.11. SGLT2 Inhibitors Market - Rest of Asia Pacific
  - 8.5.11.1. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.11.2. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.11.3. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.6. SGLT2 Inhibitors Market - Middle East & Africa
- 8.6.1. Middle East & Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.6.4. SGLT2 Inhibitors Market - Saudi Arabia
  - 8.6.4.1. Saudi Arabia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.6.4.2. Saudi Arabia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.6.4.3. Saudi Arabia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.6.5. SGLT2 Inhibitors Market - UAE
  - 8.6.5.1. UAE: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.6.5.2. UAE.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.6.5.3. UAE: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.6.6. SGLT2 Inhibitors Market - Israel
  - 8.6.6.1. Israel: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.6.6.2. Israel.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.6.6.3. Israel: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.6.7. SGLT2 Inhibitors Market - South Africa
  - 8.6.7.1. South Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.6.7.2. South Africa.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.6.7.3. South Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.6.8. SGLT2 Inhibitors Market - Rest of Middle East & Africa
  - 8.6.8.1. Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.6.8.2. Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.6.8.3. Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.7. SGLT2 Inhibitors Market - Latin America
- 8.7.1. Latin America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
- 8.7.2. Latin America.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.3. Latin America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.7.4. SGLT2 Inhibitors Market - Mexico
  - 8.7.4.1. Mexico: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.7.4.2. Mexico.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.7.4.3. Mexico: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.7.5. SGLT2 Inhibitors Market - Brazil
  - 8.7.5.1. Brazil: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.7.5.2. Brazil.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.7.5.3. Brazil: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.7.6. SGLT2 Inhibitors Market - Argentina
  - 8.7.6.1. Argentina: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.7.6.2. Argentina.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.7.6.3. Argentina: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.7.7. SGLT2 Inhibitors Market - Rest of Latin America
  - 8.7.7.1. Rest of Latin America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.7.7.2. Rest of Latin America.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.7.7.3. Rest of Latin America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. AstraZeneca
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. Boehringer Ingelheim International GmbH
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Bristol-Myers Squibb Company
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. Eli Lilly and Company
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. Glenmark Pharmaceuticals Ltd.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Lexicon Pharmaceuticals, Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Merck & Co., Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Sanofi
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. TheracosBio, LLC
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development